News
The benefit-risk balance is tipping more in favor of Eli Lilly’s Kisunla in early Alzheimer’s disease as the FDA ...
Approval was based on results from the Phase IIIb TRAILBLAZER-ALZ 6 trial, which showed that Kisunla achieved comparable ...
A new dosing regimen for Kisunla, to help lower the risk of certain side effects, has been approved by the U.S. Food and Drug ...
The newly recommended dosing schedule significantly lowered ARIA-E rates compared to the original dosing schedule, adding to ...
A slower ramp-up of Kisunla dosing lowers the rate of dangerous brain swelling, a risk that has made doctors reluctant to ...
Saturday at the Dream Center, the Bismarck Memory Cafe hosted a presentation from the Alzheimer’s Association about recent ...
A journey through the FDA’s newly released complete response letters gave glimpses into the journeys to market for Eli ...
Kisunlaâ„¢ (kih-SUHN-lah) is used to treat adults with early symptomatic Alzheimer's disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of disease.
Kisunla continues to slow Alzheimer’s progression in early-stage patients; Eli Lilly stock has risen over 400% in 5 years despite a recent pullback; Eli Lilly and Company (NYSE: LLY) stock closed at ...
The new dosing schedule with a more gradual titration significantly lowered incidence of ARIA-E in the TRAILBLAZER-ALZ 6 trial.
The US Food and Drug Administration (FDA) has approved a label update with a new recommended titration dosing schedule for ...
Lilly's Kisunla gets FDA approval for a new dosing schedule that significantly lowers ARIA-E risk while maintaining amyloid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results